Brought to you by 
GSK and XenoPort join forces on restless leg/pain agent; terminated
03 Dec 2015
Executive Summary
XenoPort (prodrug candidates for neurological and GI diseases) has licensed GlaxoSmithKline exclusive worldwide rights (excluding Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan, where Astellas Pharma already has rights) to develop, manufacture, and market XP13512, a gabapentin prodrug in Phase III for restless legs syndrome and Phase II for neuropathic pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK and XenoPort join forces on restless leg/pain agent; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice